Adaptive Biotechnologies Corporation [NASDAQ: ADPT] gained 2.30% on the last trading session, reaching $39.17 price per share at the time. The company report on September 1, 2020 that Adaptive Biotechnologies to Present at the Morgan Stanley 2020 Healthcare Conference.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.
Adaptive Biotechnologies’ management is scheduled to participate in a fireside chat on Tuesday, September 15th at 10:15 a.m. Pacific Time / 1:15 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company website at: www.adaptivebiotech.com.
Adaptive Biotechnologies Corporation represents 127.38 million in outstanding shares, while the company has a total market value of $5.46 billion with the latest information. ADPT stock price has been found in the range of $38.28 to $40.00.
If compared to the average trading volume of 1.03M shares, ADPT reached a trading volume of 1202365 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Adaptive Biotechnologies Corporation [ADPT]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ADPT shares is $54.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ADPT stock is a recommendation set at 1.50. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Adaptive Biotechnologies Corporation shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on September 09, 2020. While these analysts kept the previous recommendation, Goldman raised their target price to Buy. The new note on the price target was released on June 03, 2020, representing the official price target for Adaptive Biotechnologies Corporation stock. Previously, the target price had yet another raise to $46, while BTIG Research analysts kept a Buy rating on ADPT stock.
The Average True Range (ATR) for Adaptive Biotechnologies Corporation is set at 2.15, with the Price to Sales ratio for ADPT stock in the period of the last 12 months amounting to 59.22. The Price to Book ratio for the last quarter was 9.42, with the Price to Cash per share for the same quarter was set at 4.09.
Trading performance analysis for ADPT stock
Adaptive Biotechnologies Corporation [ADPT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.27. With this latest performance, ADPT shares gained by 6.50% in over the last four-week period, additionally plugging by 121.55% over the last 6 months – not to mention a drop of -6.20% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ADPT stock in for the last two-week period is set at 46.25, with the RSI for the last a single of trading hit 48.19, and the three-weeks RSI is set at 47.66 for Adaptive Biotechnologies Corporation [ADPT]. The present Moving Average for the last 50 days of trading for this stock 40.83, while it was recorded at 37.25 for the last single week of trading, and 34.02 for the last 200 days.
Adaptive Biotechnologies Corporation [ADPT]: A deeper dive into fundamental analysis
Operating Margin for any stock indicates how profitable investing would be, and Adaptive Biotechnologies Corporation [ADPT] shares currently have an operating margin of -92.15 and a Gross Margin at +65.86. Adaptive Biotechnologies Corporation’s Net Margin is presently recorded at -81.78.
Return on Total Capital for ADPT is now -17.22, given the latest momentum, and Return on Invested Capital for the company is -15.28. Return on Equity for this stock declined to -44.46, with Return on Assets sitting at -11.18. When it comes to the capital structure of this company, Adaptive Biotechnologies Corporation [ADPT] has a Total Debt to Total Equity ratio set at 6.41. Additionally, ADPT Total Debt to Total Capital is recorded at 6.02, with Total Debt to Total Assets ending up at 4.01. Long-Term Debt to Equity for the company is recorded at 6.41, with the Long-Term Debt to Total Capital now at 6.02.
Reflecting on the efficiency of the workforce at the company, Adaptive Biotechnologies Corporation [ADPT] managed to generate an average of -$153,576 per employee. Receivables Turnover for the company is 9.73 with a Total Asset Turnover recorded at a value of 0.14.Adaptive Biotechnologies Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 6.30 and a Current Ratio set at 6.40.
Adaptive Biotechnologies Corporation [ADPT]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, Adaptive Biotechnologies Corporation posted -0.11/share EPS, while the average EPS was predicted by analysts to be reported at -0.24/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 54.20%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ADPT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Adaptive Biotechnologies Corporation go to 3.90%.
An analysis of insider ownership at Adaptive Biotechnologies Corporation [ADPT]
There are presently around $3,951 million, or 74.60% of ADPT stock, in the hands of institutional investors. The top three institutional holders of ADPT stocks are: VIKING GLOBAL INVESTORS LP with ownership of 33,493,708, which is approximately 0% of the company’s market cap and around 1.40% of the total institutional ownership; MATRIX CAPITAL MANAGEMENT COMPANY, LP, holding 15,115,090 shares of the stock with an approximate value of $592.06 million in ADPT stocks shares; and VANGUARD GROUP INC, currently with $220.97 million in ADPT stock with ownership of nearly 26.156% of the company’s market capitalization.
Positions in Adaptive Biotechnologies Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 130 institutional holders increased their position in Adaptive Biotechnologies Corporation [NASDAQ:ADPT] by around 11,891,930 shares. Additionally, 64 investors decreased positions by around 7,819,584 shares, while 19 investors held positions by with 81,149,339 shares. The mentioned changes placed institutional holdings at 100,860,853 shares, according to the latest SEC report filing. ADPT stock had 67 new institutional investments in for a total of 3,249,755 shares, while 13 institutional investors sold positions of 713,336 shares during the same period.